ABL001 is a potent and selective ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Ph + acute lymphoblastic leukemia [69]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.